staurosporine has been researched along with deoxycytidine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouffard, DY; Momparler, RL | 1 |
| Chan, TS; Sato, T | 1 |
| Azuma, A; Huang, P; Li, YX; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Alvarez, E; Bergman, AM; Eriksson, S; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; van Groeningen, CJ | 1 |
| Berthaud, P; Faivre, S; Henriksson, R; Le Chevalier, T; Monnerat, C; Novello, S; Raymond, E | 1 |
| Bergman, AM; Hoebe, EK; Leon, LG; Loves, WJ; Peters, GJ; Sigmond, J | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC | 1 |
| Beeharry, N; Caviston, JP; Rattner, JB; Yen, T | 1 |
1 trial(s) available for staurosporine and deoxycytidine
| Article | Year |
|---|---|
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Enzyme Inhibitors; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Staurosporine | 2004 |
8 other study(ies) available for staurosporine and deoxycytidine
| Article | Year |
|---|---|
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Northern; Cytarabine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Gene Expression; Genes, fos; Genes, jun; HL-60 Cells; Humans; Leukemia, T-Cell; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Deoxyadenosine blockade of G0 to G1 transition in lymphocytes: possible involvement of protein kinases.
Topics: Alkaloids; Animals; Blotting, Western; Calcium; Cell Death; Cells, Cultured; Concanavalin A; Deoxyadenosines; Deoxycytidine; Drug Synergism; Flow Cytometry; G1 Phase; Lymphocyte Activation; Lymphocytes; Mice; Mice, Inbred Strains; Protein Kinases; Resting Phase, Cell Cycle; Spleen; Staurosporine; Thymidine | 1996 |
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Leukemia, Myeloid, Acute; S Phase; Staurosporine; Tumor Cells, Cultured | 2001 |
The role of deoxycytidine kinase in gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Colorectal Neoplasms; Deoxycytidine; Deoxycytidine Kinase; Dexamethasone; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Glucocorticoids; HL-60 Cells; Humans; Protein Kinase C; Ribonucleotide Reductases; RNA, Messenger; Staurosporine; Tumor Cells, Cultured; U937 Cells | 2000 |
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Protein Kinase C; Ribonucleotide Reductases; Staurosporine | 2010 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |
Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Centromere; Checkpoint Kinase 1; CHO Cells; Comet Assay; Cricetinae; Cricetulus; Deoxycytidine; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; G2 Phase Cell Cycle Checkpoints; Gemcitabine; HeLa Cells; Humans; Kinetochores; Mitosis; Protein Kinases; S Phase Cell Cycle Checkpoints; Staurosporine; Topoisomerase II Inhibitors | 2013 |